Tadalafil is under clinical development by IntelGenx and currently in the Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tadalafil’s likelihood of approval (LoA) and phase transition for Erectile Dysfunction took place on 30 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tadalafil Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tadalafil overview

Tadalafil (INT-0007) is under development for the treatment of erectile dysfunction (ED). It is an oral film formulation. INT-007 is developed using quick-release water technology called Versafilm. This technology utilizes a strip of thin polymeric film, which instantly releases the drug candidate.

IntelGenx overview

IntelGenx is a Canadian oral drug delivery company. It develops pharmaceutical oral films based on its proprietary technology platform, VersaFilm.

Quick View Tadalafil LOA Data

Report Segments
  • Innovator
Drug Name
  • Tadalafil
Administration Pathway
  • Oral
Therapeutic Areas
  • Male Health
Key Developers
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.